Faculty of Dentistry, McGill University, 740 Rue Dr. Penfield Suite # 4300, Montréal, QC, H3A 1A4, Canada.
Biotechnol Lett. 2009 Dec;31(12):1817-24. doi: 10.1007/s10529-009-0099-x. Epub 2009 Aug 19.
Recombinant human bone morphogenetic proteins (rhBMPs) have been extensively investigated for developing therapeutic strategies aimed at the restoration and treatment of orthopaedic as well as craniofacial conditions. In this first part of the review, we discuss the rationale for the necessary use of carrier systems to deliver rhBMP-2 and rhBMP-7 to sites of bone tissue regeneration and repair. General requirements for growth factor delivery systems emphasizing the distinction between localized and release-controlled delivery strategies are presented highlighting the current limitations in the development of an effective rhBMP delivery system applicable in clinical bone tissue engineering.
重组人骨形态发生蛋白(rhBMPs)已被广泛研究,以开发旨在恢复和治疗骨科以及颅面状况的治疗策略。在本综述的第一部分中,我们讨论了使用载体系统将 rhBMP-2 和 rhBMP-7 递送到骨组织再生和修复部位的必要性的基本原理。介绍了生长因子递送系统的一般要求,强调了局部和释放控制递送策略之间的区别,突出了当前在开发适用于临床骨组织工程的有效 rhBMP 递送系统方面的局限性。